Shanghai Allist Pharmaceuticals Co. Ltd.SSE: 688578

(688578)"SHANGHAI ALLIST PHARMACEUTICALS CO., LTD."Announcement on Progress of the Pivotal Clinical Trial of Furmonertinib for First-line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations

· Issued by Shanghai Allist Pharmaceuticals Co. Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 688578 · · 3 pages · Chinese

Summary by 6ix AI

The trial, known as FURVENT, did not meet its primary endpoint of progression-free survival as assessed by independent review. However, clinical benefits were observed in secondary endpoints, and safety data were consistent with previous studies. The company is evaluating the complete dataset to determine future steps regarding the drug's development.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

On 6ix: 6ix.com/news/688578shanghai-allist-pharmaceuticals-co-ltdannouncement-on-progress-of-the-pivotal-clinical-trial-of-furmonertinib-for-first-line-treatment-of-nsclc-with-egfr-exon-20-insertion-mutations

Release

Announcement on Progress of the Pivotal Clinical Trial of Furmonertinib for First-line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Shanghai Allist Pharmaceuticals Co. Ltd. on 6ix

Story so far

Earlier from Shanghai Allist Pharmaceuticals

Later from Shanghai Allist Pharmaceuticals

All Shanghai Allist Pharmaceuticals news releases